Literature DB >> 22065917

Evaluation of topical cysteamine therapy in the CTNS(-/-) knockout mouse using in vivo confocal microscopy.

Jennifer L Simpson1, Chyong Jy Nien, Kevin J Flynn, James V Jester.   

Abstract

PURPOSE: The purpose of this study was to assess the ability of quantitative in vivo confocal microscopy (CM) to detect changes in cystine crystal volume in the cystinosisn (Ctns(-/-))mouse cornea following topical cysteamine therapy.
METHODS: Fifteen Ctns(-/-) mice were sequentially followed using in vivo CM from 3 to 10 months of age. In a second experiment, five mice receiving topical cysteamine eyedrops (0.55%) for 4 weeks were compared to five untreated mice. The volume of corneal cystine crystals was determined by thresholding and counting high intensity pixels in the in vivo CM scans and dividing by the stromal volume to calculate a crystal volume index (CVI).
RESULTS: Corneal crystals progressively increased in density with age, reaching a peak density at 6-8 months and showing a 70 fold increase in CVI. Eyes treated with cysteamine drops showed significantly less crystal accumulation compared to control eyes (p<0.001) with only a 15% increase in treated eyes (p=ns) compared to 173% increase (p<0.04) for untreated eyes.
CONCLUSIONS: Measurement of CVI shows that there is a progressive increase in cystine crystal volume up to 8 months of age and that cysteamine eyedrops significantly inhibits progression in the Ctns(-/-) mouse. These findings are similar to those seen clinically in patients with cystinosis, and suggest that measurement of CVI in the Ctns(-/-) mouse may be used as a model to develop novel therapeutic strategies for treating corneal cystinosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065917      PMCID: PMC3209421     

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


  35 in total

Review 1.  Pharmacological treatment of nephropathic cystinosis with cysteamine.

Authors:  Robert Kleta; William A Gahl
Journal:  Expert Opin Pharmacother       Date:  2004-11       Impact factor: 3.889

2.  Age-related prevalence of anterior segment complications in patients with infantile nephropathic cystinosis.

Authors:  Ekaterini T Tsilou; Benjamin I Rubin; George F Reed; Fumino Iwata; William Gahl; Muriel I Kaiser-Kupfer
Journal:  Cornea       Date:  2002-03       Impact factor: 2.651

3.  Molecular characterization of CTNS deletions in nephropathic cystinosis: development of a PCR-based detection assay.

Authors:  L Forestier; G Jean; M Attard; S Cherqui; C Lewis; W van't Hoff; M Broyer; M Town; C Antignac
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

4.  A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis.

Authors:  M I Kaiser-Kupfer; M A Gazzo; M B Datiles; R C Caruso; E M Kuehl; W A Gahl
Journal:  Arch Ophthalmol       Date:  1990-05

5.  The penetration of topical cysteamine into the human eye.

Authors:  J D Hsuan; J J Harding; A J Bron
Journal:  J Ocul Pharmacol Ther       Date:  1996       Impact factor: 2.671

6.  CTNS mutations in an American-based population of cystinosis patients.

Authors:  V Shotelersuk; D Larson; Y Anikster; G McDowell; R Lemons; I Bernardini; J Guo; J Thoene; W A Gahl
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

7.  Identification of 14 novel CTNS mutations and characterization of seven splice site mutations associated with cystinosis.

Authors:  Vasiliki Kalatzis; Lola Cohen-Solal; Béatrice Cordier; Yaacov Frishberg; Markus Kemper; E Matti Nuutinen; Eric Legrand; Pierre Cochat; Corinne Antignac
Journal:  Hum Mutat       Date:  2002-12       Impact factor: 4.878

8.  The ocular anomalies in a cystinosis animal model mimic disease pathogenesis.

Authors:  Vasiliki Kalatzis; Nicolas Serratrice; Claire Hippert; Olivier Payet; Carl Arndt; Chantal Cazevieille; Tangui Maurice; Christian Hamel; François Malecaze; Corinne Antignac; Agnes Müller; Eric J Kremer
Journal:  Pediatr Res       Date:  2007-08       Impact factor: 3.756

9.  Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy.

Authors:  William A Gahl; Joan Z Balog; Robert Kleta
Journal:  Ann Intern Med       Date:  2007-08-21       Impact factor: 25.391

10.  Quantitative in vivo and ex vivo confocal microscopy analysis of corneal cystine crystals in the Ctns knockout mouse.

Authors:  Jennifer Simpson; Chyong Jy Nien; Kevin Flynn; Brian Jester; Stephanie Cherqui; James Jester
Journal:  Mol Vis       Date:  2011-08-17       Impact factor: 2.367

View more
  3 in total

1.  Treatment of Inherited Eye Defects by Systemic Hematopoietic Stem Cell Transplantation.

Authors:  Celine J Rocca; Alexander Kreymerman; Sarah N Ur; Katie E Frizzi; Swati Naphade; Athena Lau; Tammy Tran; Nigel A Calcutt; Jeffrey L Goldberg; Stephanie Cherqui
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-11       Impact factor: 4.799

Review 2.  Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases.

Authors:  Jacob M Favret; Nadav I Weinstock; M Laura Feltri; Daesung Shin
Journal:  Front Mol Biosci       Date:  2020-04-15

Review 3.  Cysteamine hydrochloride eye drop solution for the treatment of corneal cystine crystal deposits in patients with cystinosis: an evidence-based review.

Authors:  Achini K Makuloluwa; Fatemeh Shams
Journal:  Clin Ophthalmol       Date:  2018-01-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.